Technology
Health
Pharmaceutical

Reata Pharmaceuticals

$91.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.89 (-2.03%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell RETA and other stocks, options, ETFs, and crypto commission-free!

About

Reata Pharmaceuticals, Inc. Class A Common Stock, also called Reata Pharmaceuticals, is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Read More Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.

Employees
123
Headquarters
Irving, Texas
Founded
2002
Market Cap
2.76B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
286.47K
High Today
$93.37
Low Today
$90.16
Open Price
$92.92
Volume
83.78K
52 Week High
$104.53
52 Week Low
$19.31

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2016 IPO
US
North America

News

MarketBeatMar 6

Stock Price, News, & Analysis for Reata Pharmaceuticals

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertensi...

21
Simply Wall StMar 1

When Can We Expect A Profit From Reata Pharmaceuticals, Inc. (NASDAQ:RETA)?

Reata Pharmaceuticals, Inc.’s (NASDAQ:RETA): Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company’s loss has recently broadened since it announced a -US$47.7m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$71.6m, moving ...

120
Seeking AlphaFeb 28

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q4 2018 Results - Earnings Call Transcript

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q4 2018 Results Earnings Conference Call February 27, 2019 8:00 PM ET Company Participants Vinny Jindal - VP, Strategy Warren Huff - CEO Colin Meyer - CMO Jason Wilson - CFO Conference Call Participants Yigal Nochomovitz - Citigroup Adam Walsh - Stifel Maury Raycroft - Jefferies Brian Skorney - Baird Charles Duncan - Cantor Matt Kaplan - Ladenburg Thalmann Operator Good day, ladies and gentlemen, and welcome to the Reata Fourth Quarter and Financial Re...

19

Earnings

-$1.08
-$0.67
-$0.26
$0.15
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.